Disappointing outcome of autologous stem cell transplantation for enteropathy-associated T-cell lymphoma

Dig Liver Dis. 2007 Jul;39(7):634-41. doi: 10.1016/j.dld.2007.03.009. Epub 2007 May 24.


Background: Despite treatment, enteropathy-associated T-cell lymphoma has a very poor outcome. Chemotherapy can be complicated by small bowel perforation, gastrointestinal bleeding and development of enterocolic fistulae. Here we report on the feasibility, safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma (three upfront and one at relapse), with or without prior partial small bowel resection.

Methods: Four patients [two males, two females, mean age 65 years (range 60-69 years)] received high-dose chemotherapy followed by autologous stem cell transplantation. Partial small bowel resection has been performed in three patients.

Results: All four patients completed the mobilization and leucopheresis procedures successfully and subsequently received conditioning chemotherapy and transplantation. Engraftment occurred in all patients. No major non-haematological toxicity or transplantation-related mortality was observed. One patient has ongoing complete remission 32 months after transplantation. Three patients died from relapse within few months after autologous stem cell transplantation.

Conclusions: Autologous stem cell transplantation seems unsatisfactory for patients with enteropathy-associated T-cell lymphoma. More intensive conditioning and aggressive chemotherapy with/or without targeted immunotherapy as well as allogenous stem cell transplantation needs to be explored.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Celiac Disease / complications*
  • Celiac Disease / therapy*
  • Feasibility Studies
  • Female
  • Humans
  • Ileum / pathology
  • Lymphoma, T-Cell / complications*
  • Lymphoma, T-Cell / etiology
  • Lymphoma, T-Cell / therapy*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Peripheral Blood Stem Cell Transplantation*
  • Remission Induction
  • Transplantation Conditioning*
  • Transplantation, Autologous
  • Treatment Outcome